P-147 Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Yuki, S., Komatsu, Y., Nakatsumi, H., Kawamoto, Y., Muranaka, T., Sawada, K., Tsuji, Y., Hosokawa, A., Nakamura, M., Muto, O., Sasaki, T., Iwanaga, I., Hatanaka, K., Sato, A., Eto, K., Furukawa, K., Tateyama, M., Takahashi, Y., Sogabe, S., Honda, T., Sakamoto, N., Sakata, Y.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2016
Teme:
Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4983925/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw199.141
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki